Actelion and GSK Discontinue Clinical Development of Almorexant
Advertisement
Actelion Ltd and GlaxoSmithKline announced that clinical development of the Phase III investigational dual orexin receptor antagonist, almorexant, has been discontinued. This decision follows a review of data from additional clinical studies, which were conducted to further establish the clinical profile of almorexant, including the tolerability profile.
GSK and Actelion remain committed to conducting further research to better understand the potential of orexin receptor antagonism in sleep disorders and other indications. Both companies will continue to work on the discovery and development of new orexin receptor antagonist therapies, based on the orexin alliance formed in July 2008.